IMTX
Price
$9.41
Change
+$0.02 (+0.21%)
Updated
Oct 7, 04:59 PM (EDT)
Capitalization
1.14B
41 days until earnings call
RCUS
Price
$14.03
Change
-$0.45 (-3.11%)
Updated
Oct 7 closing price
Capitalization
1.49B
34 days until earnings call
Interact to see
Advertisement

IMTX vs RCUS

Header iconIMTX vs RCUS Comparison
Open Charts IMTX vs RCUSBanner chart's image
Immatics
Price$9.41
Change+$0.02 (+0.21%)
Volume$14.73K
Capitalization1.14B
Arcus Biosciences
Price$14.03
Change-$0.45 (-3.11%)
Volume$1.19M
Capitalization1.49B
IMTX vs RCUS Comparison Chart in %
IMTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMTX vs. RCUS commentary
Oct 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMTX is a Buy and RCUS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 08, 2025
Stock price -- (IMTX: $9.41 vs. RCUS: $14.03)
Brand notoriety: IMTX and RCUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMTX: 148% vs. RCUS: 134%
Market capitalization -- IMTX: $1.14B vs. RCUS: $1.49B
IMTX [@Biotechnology] is valued at $1.14B. RCUS’s [@Biotechnology] market capitalization is $1.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $105.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMTX’s FA Score shows that 0 FA rating(s) are green whileRCUS’s FA Score has 0 green FA rating(s).

  • IMTX’s FA Score: 0 green, 5 red.
  • RCUS’s FA Score: 0 green, 5 red.
According to our system of comparison, both IMTX and RCUS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMTX’s TA Score shows that 6 TA indicator(s) are bullish while RCUS’s TA Score has 3 bullish TA indicator(s).

  • IMTX’s TA Score: 6 bullish, 4 bearish.
  • RCUS’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, IMTX is a better buy in the short-term than RCUS.

Price Growth

IMTX (@Biotechnology) experienced а +10.45% price change this week, while RCUS (@Biotechnology) price change was +3.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.19%. For the same industry, the average monthly price growth was +15.97%, and the average quarterly price growth was +89.17%.

Reported Earning Dates

IMTX is expected to report earnings on Nov 18, 2025.

RCUS is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+8.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCUS($1.49B) has a higher market cap than IMTX($1.14B). IMTX YTD gains are higher at: 32.349 vs. RCUS (-5.776). IMTX has higher annual earnings (EBITDA): -58.05M vs. RCUS (-282M). RCUS has more cash in the bank: 911M vs. IMTX (478M). IMTX has less debt than RCUS: IMTX (17.1M) vs RCUS (109M). RCUS has higher revenues than IMTX: RCUS (262M) vs IMTX (130M).
IMTXRCUSIMTX / RCUS
Capitalization1.14B1.49B77%
EBITDA-58.05M-282M21%
Gain YTD32.349-5.776-560%
P/E Ratio27.61N/A-
Revenue130M262M50%
Total Cash478M911M52%
Total Debt17.1M109M16%
FUNDAMENTALS RATINGS
IMTX vs RCUS: Fundamental Ratings
IMTX
RCUS
OUTLOOK RATING
1..100
2175
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
62
Fair valued
PROFIT vs RISK RATING
1..100
95100
SMR RATING
1..100
9597
PRICE GROWTH RATING
1..100
3639
P/E GROWTH RATING
1..100
6499
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCUS's Valuation (62) in the Pharmaceuticals Major industry is in the same range as IMTX (72) in the null industry. This means that RCUS’s stock grew similarly to IMTX’s over the last 12 months.

IMTX's Profit vs Risk Rating (95) in the null industry is in the same range as RCUS (100) in the Pharmaceuticals Major industry. This means that IMTX’s stock grew similarly to RCUS’s over the last 12 months.

IMTX's SMR Rating (95) in the null industry is in the same range as RCUS (97) in the Pharmaceuticals Major industry. This means that IMTX’s stock grew similarly to RCUS’s over the last 12 months.

IMTX's Price Growth Rating (36) in the null industry is in the same range as RCUS (39) in the Pharmaceuticals Major industry. This means that IMTX’s stock grew similarly to RCUS’s over the last 12 months.

IMTX's P/E Growth Rating (64) in the null industry is somewhat better than the same rating for RCUS (99) in the Pharmaceuticals Major industry. This means that IMTX’s stock grew somewhat faster than RCUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMTXRCUS
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 1 day ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 7 days ago
77%
Bullish Trend 8 days ago
81%
Declines
ODDS (%)
Bearish Trend 23 days ago
79%
Bearish Trend 5 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 1 day ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
IMTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PSPJX32.21N/A
N/A
Principal Large Cap S&P 500 Index J
STCIX10.22N/A
N/A
Virtus Silvant Large-Cap Growth Stk A
PSIJX9.13N/A
N/A
Principal SmallCap Growth I J
FBSIX39.15N/A
N/A
Franklin Mutual U.S. Mid Cap Value R6
SSCDX18.92N/A
N/A
Sit Small Cap Dividend Growth I

IMTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMTX has been loosely correlated with IDYA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if IMTX jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMTX
1D Price
Change %
IMTX100%
+0.21%
IDYA - IMTX
52%
Loosely correlated
-2.07%
IMNM - IMTX
50%
Loosely correlated
-4.09%
XNCR - IMTX
49%
Loosely correlated
+2.04%
OCUL - IMTX
48%
Loosely correlated
+5.01%
NRIX - IMTX
48%
Loosely correlated
-1.21%
More